Trial · NCT07122102
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes
NCT07122102, Not applicable, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes. Trials, record NCT07122102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07122102
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes
- NCT number
- NCT07122102
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Conditions
- Type 2 Diabetes
- Interventions
- Cofrogliptin, Acarbose
- First posted
- 2025-08-14
- Last updated
- 2025-09-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HbA1c | From enrollment to the end of treatment at 12 weeks | The difference in HbA1c from the baseline |
| Secondary | FPG (Fasting plasma glucose) | From enrollment to the end of treatment at 12 weeks | The difference in FPG from the baseline |
| Secondary | 2h-PPG (2-hour postprandial glucose) | From enrollment to the end of treatment at 12 weeks | The difference in 2h-PPG from the baseline |
| Secondary | Fasting C-peptide | From enrollment to the end of treatment at 12 weeks | The difference in fasting C-peptide from the baseline |
| Secondary | Insulin sensitivity | From enrollment to the end of treatment at 12 weeks | The difference in insulin sensitivity from the baseline |
| Secondary | Islet function | From enrollment to the end of treatment at 12 weeks | The difference in Islet function from the baseline |
| Secondary | Body weight | From enrollment to the end of treatment at 12 weeks | The difference in body weight from the baseline |
| Secondary | Intestinal microbial composition and functional characteristics | From enrollment to the end of treatment at 12 weeks | The difference in intestinal microbial composition and functional characteristics from the baseline |
| Secondary | Incidence of hypoglycemia | From enrollment to the end of safety visitation at 13 weeks | The percentage of subjects who experienced any investigator-defined hypoglycemic adverse event |
| Secondary | Gastrointestinal adverse events | From enrollment to the end of safety visitation at 13 weeks | The percentage of subjects who experienced any investigator-defined gastrointestinal adverse events adverse event |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07122102
GET https://conductscience.org/api/trials/v1/NCT07122102/registered